Bavarian-CEO: operational improvements will continue
Even though profitability of production has been significantly improved in Bavarian Nordic, the company will still become more efficient, says the CEO, who also explains why.
af KRESTEN MORTEN MUNKSGAARD
A more efficient production of the small pox vaccine Imvamune has enabled the Danish company Bavarian Nordic to supply more vaccines to US authorities than expected. The company has now enhanced expectations for 2012.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
US government expands use of Danish vaccine
For abonnenter
Bavarian-CEO: ”Yellow fever, hepatitis, you name it”
For abonnenter
Bavarian strikes a new deal with the US government
For abonnenter
